Abraham P A, Opsahl J A, Halstenson C E, Chremos A N, Matzke G R, Keane W F
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota 55415.
Br J Clin Pharmacol. 1987 Sep;24(3):385-9. doi: 10.1111/j.1365-2125.1987.tb03185.x.
The effect of famotidine, a new histamine H2-receptor antagonist, on renal tubular creatinine secretion was evaluated in twelve patients with reduced renal function (creatinine clearance 10-60 ml min-1). Creatinine and inulin clearances were determined at baseline and for 4 h after a 10 mg intravenous dose of famotidine. Famotidine renal clearance exceeded inulin clearance by an average of 152%, indicating that renal tubular secretion of famotidine occurred. No significant changes in the clearances of creatinine or inulin, or the fractional clearance of creatinine were observed after famotidine administration. These data suggest that famotidine, unlike cimetidine, does not inhibit renal tubular secretion of creatinine. Thus, famotidine does not affect creatinine-dependent measurements of renal function and is unlikely to alter the renal elimination of basic drugs.
在12例肾功能减退(肌酐清除率为10 - 60 ml/min)的患者中评估了新型组胺H2受体拮抗剂法莫替丁对肾小管肌酐分泌的影响。在静脉注射10 mg法莫替丁之前及之后4小时测定肌酐清除率和菊粉清除率。法莫替丁的肾清除率平均超过菊粉清除率152%,表明法莫替丁存在肾小管分泌。给予法莫替丁后,肌酐或菊粉清除率以及肌酐分数清除率均未观察到显著变化。这些数据表明,与西咪替丁不同,法莫替丁不抑制肾小管肌酐分泌。因此,法莫替丁不影响依赖肌酐的肾功能测量,并且不太可能改变碱性药物的肾脏清除。